The global brain-computer interface (BCI) industry is ramping up recruitment of commercialization talent to build momentum for product monetization. Leading overseas players such as Precision Neuroscience and Neuralink are bringing in executives with end-to-end experience in medical device commercialization, while domestic companies including Gestalt and Boruikang are also expanding their commercialization teams, with related roles offering salaries of up to one million yuan. The industry's commercialization window officially opens in 2026, with three factors—clinical data, regulatory and reimbursement pathways, and capital competition—jointly driving the industry's focus from technical validation toward implementation and monetization. What companies are competing for is not ordinary salespeople, but scarce talent who have successfully navigated the entire closed loop of product approval, medical insurance coverage, and hospital channel deployment. Yet having the right people in place is only the first step; the industry still needs to overcome challenges such as insufficient long-term product stability, difficulty in achieving market scale-up, and high costs. The long race toward large-scale commercialization has only just begun.
